Dr Reddys Laboratories
Growth Strategy & Outlook
Growth Transition & Strategic Focus
- DRRD is rebuilding growth to offset the anticipated gRevlimid sales decline.
- Transition includes higher R&D costs, complex product launches, and timeline uncertainties in biosimilars.
- Management flagged flexibility to cut discretionary costs by 500–600 bps, but this may be limited due to the need to fund FY27E–30E launches.
Biosimilar & API Opportunities
- Biosimilars remain a key growth lever:
- Two biosimilars in Europe (FY26E): each with $40–50 Mn revenue potential.
- Denosumab launch expected in FY27E (~$50 Mn opportunity).
- Investing ₹2,500 Cr in GLP-1 API (e.g., Semaglutide); FY27E potential: $150–200 Mn.
- GLP-1 market expected to grow 5x over the next 5–6 years.
Consumer Health & Strategic Expansions
- Building resilience beyond gRevlimid:
- Acquisitions: Menolabs (US), Haleon’s NRT portfolio (Europe), Nestlé JV in India.
- Focused on consumer health and diversified geographies.
R&D & Biosimilar Pipeline
- 20% of R&D spend allocated to biosimilars.
- Key launches/filings:
- Bevacizumab (UK)
- Rituximab (EU/UK)
- Denosumab filings (US/EU)
- Strategic tie-ups with Alvotech, Henlius, Bio-Thera, Coya, expanding biosimilar reach.
Recommendation by Broking Firms (Updated on 25th July 2025)
| Issuing Company | Rating | Target Price |
| Axis Research | Hold | 1360 |
| Antique Stock Broking | Sell | 1110 |
| B&K Securities | Buy | 1500 |
| J M Financial | Buy | 1521 |
| Centrum | Buy | 1510 |
| Average Target Price | 1400 | |
Reports
Recent Concall Highlights
Pipeline & Product Launches
- 49 new launches across markets in Q1FY26.
- 20 US launches planned in FY26, including Semaglutide and Liraglutide.
- Canada launch of Semaglutide expected in CY26; approval by Oct–Nov 2025.
- GLP-1, biosimilars (Abatacept, Denosumab), and complex generics are key focus areas.
Operational & Strategic Updates
- Maintains FY26 EBITDA margin guidance of 25%+.
- R&D spend at 7–7.5% of sales.
- Filed 12 DMFs and 11 global generics in Q1.
- Capex of ₹25–27 bn allocated to peptides and biosimilars.
- Regulatory inspections received Form 483s; responses submitted.